News and best practices from members of the World Alliance of Pituitary Organizations – WAPO – and other interesting global developments.
One of the most valuable things you can do to help the pituitary community is share your own experience. What you have lived through helps others understand the realities of living with acromegaly, or any other disease. It helps clinicians see challenges that never show up in a lab result and helps make sure that programs and services are built on patients needs. Taking part in research and using your voice is one of the most direct ways to do that.
Acromegaly patients and healthcare providers worldwide can participate in this survey designed to provide information that may help improve quality of life during the COVID-19 pandemic. Much of this initiative’s success will depend on your
Dr. Manel Puig Domingo, a leading endocrinologist in Barcelona, is doing important work on facial recognition and biometrics to see if this technology is useful in recognizing the early physical changes that occur in Acromegaly.
Note: Muscle weakness affects the quality of life in people with acromegaly. Doctora Elena Valassi takes a fascinating look at what happens to muscles when exposed to excess Growth Hormone. Her work is of paramount
If you’d like to learn more about Addison’s disease, here’s a perfect opportunity to do so. The Advanced Practice in Endocrinology Nursing is a comprehensive resource on Adrenal Insufficiency and three chapters from the book are
The Chilean pituitary patient advocacy group, Corapehi presents information on the use of traditional Chinese medicine techniques to aid in managing stress and improve emotional well being. The presentation is slated for this Saturday, May
This is a series of urgent clinical guidance documents on the management of endocrine conditions in the time of COVID-19. This clinical guidance document underwent expedited open peer review by Jérôme Bertherat (Paris, France), André
We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at
From J D Faccinetti – co-founder – One of the unforeseen consequences of this crisis is how it has affected our editorial decisions, that is, deciding what to write and when to publish. The media
WAPO’s Global Pituitary Voice – April 2020 edition – is now available to download. This newsletter is being released in the midst of the COVID-19 pandemic, which forced the postponement of the WAPO Summit to
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
This article caught my attention since so much of what we do today is based on big data. This coronavirus situation is no different. In the article John P.A. Ioannidis – professor of medicine, of